Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: apriluv	3/29/2016 7:55:39 PM
	of 2026

FISPEMIFENE PROGRAM FOCUS RETURNING TO LUTS (LOWER URINARY TRACT SYMPTOMS)DATE: MARCH 29, 2016 \| AUTHOR: FORENDO PHARMAOur US development and licensing partner, Apricus Biosciences Inc., yesterday announced ( link to press release) their phase 2b results of Fispemifene for the treatment of sexual dysfunction in men with secondary hypogonadism. Although the testosterone levels were significantly elevated, the symptomatic endpoints were not met in this study population. Fispemifene was well tolerated by the patients, so its’ safety profile remains attractive. Opportunities for Fispemifene in other male urological conditions have already been studied by our company in the past and we will now return our focus into LUTS and chronic prostatitis opportunities. Fispemifene as a SERM (selective estrogen receptor modulator) has a novel mechanism of action and we continue to strongly believe in its potential for multiple indications. We will continue licensing discussions with partner candidates in the field of male urological conditions.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next